Nuvation Bio Inc.
Here’s whether Nuvation Bio Inc. (NUVB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +170.2%. Concerns: 50-day MA is falling (-3.50% over 10 days); RSI 76 — overbought, elevated pullback risk; 3-month momentum negative (-13.2%); declining volume on rally — weak conviction (0.80x 30d avg). Currently 47.9% off its 52-week high. Score: +0/7.
NUVB is in a confirmed uptrend, trading above both its 50-day ($4.91) and 200-day ($4.82) moving averages. With an RSI of 76.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +170.2% compares to +35.1% for SPY (beat the market by 135.1%). The current 47.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.